文献速递癫痫

难治性局灶性癫痫发作频率长期趋势:HEP2前瞻性观察研究

Seizure Frequency Trends Over Time in Treatment-Resistant Focal Epilepsy.
PubMed 文献 · JAMA Neurol · 2025-01-01

HEP2研究纳入146例难治性局灶性癫痫患者,随访18-36个月,发现68.3%的患者在参与后半段发作频率较前半段减少,总体模型月发作频率降低68.73%(95%CI 52.92%-84.54%)。添加抗癫痫药物者中66.7%发作减少,但达到无发作概率低;使用设备的患者发作轨迹与未使用者无显著差异。

要点

  • 难治性局灶性癫痫患者发作频率随时间有改善趋势
  • 添加抗癫痫药物后仅少数达到无发作,但多数发作减少
  • 设备治疗者的发作轨迹与未使用者相似

核心结论

  • HEP2研究提示难治性局灶性癫痫发作频率随时间改善,添加抗癫痫药物达到无发作概率低但有助于减少发作,设备治疗者与未治疗者发作轨迹相似。

研究设计与样本

  • 前瞻性、观察性、多中心研究,2018年5月至2021年9月在美国10个癫痫中心纳入146例难治性局灶性癫痫患者,随访18至36个月。

主要发现

  • 146例中128例提供足够发作数据,共86例(68.3%)在参与后半段发作频率较前半段减少。
  • 总体模型月发作频率平均降低68.73%(95%CI 52.92%-84.54%)。
  • 0-12个月队列平均降低67.76%(95%CI 19.42%-116.09%);12-24个月降低36.00%(95%CI 9.27%-53.46%);>24个月降低66.03%(95%CI 48.25%-83.80%),均P<.001。
  • 69例(54.7%)添加抗癫痫药物,其中46例(66.7%)发作频率降低,包括无发作。
  • 35例使用植入设备,设备使用者的发作轨迹与无设备者无显著差异。

关键数值与推荐

  • 纳入标准:局灶性癫痫诊断、年龄16-65岁、4种及以上抗癫痫药物失败(其中至少2种因发作控制失败)。

临床怎么用

  • 对难治性局灶性癫痫,发作频率随时间可能改善,但添加药物达到无发作概率低;设备治疗与未治疗者轨迹相似,需谨慎解读开放标签研究的疾病修饰效应。

局限性

  • 观察性设计无法区分发作改善反映自然病史还是积极管理;样本为志愿者样本;仅1例在研究期间接受癫痫手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Open-label trials of antiseizure medications (ASMs) and devices suggest seizure reduction in focal treatment-resistant epilepsy (FTRE) may demonstrate treatment-related disease-modifying effects. Understanding FTRE trends can provide insight into treatment responses. OBJECTIVE: To determine whether seizure frequency in FTRE improves over time. DESIGN, SETTING, AND PARTICIPANTS: The Human Epilepsy Project 2 was a prospective, observational, multicenter study of patients with FTRE from May 2018 to September 2021 who were followed up for 18 to 36 months at 10 US-based comprehensive epilepsy centers. Analysis was performed from 2021 to 2024. Study data included seizure frequency, medication use, device use, surgeries tracked using daily electronic diaries, monthly check-ins, medical record review, and case report forms. Eligibility criteria included focal epilepsy diagnosis, age between 16 and 65 years, and failure of 4 or more ASMs (≥2 due to seizure control failure). Participants were recruited as a volunteer sample. EXPOSURES: Participants were treated with multiple interventions at their physicians' discretion. MAIN OUTCOMES AND MEASURES: The primary outcome was seizure frequency trends, evaluated by quantifying seizure freedom rates and frequency reductions. Medication and device treatment responses were assessed by tracking ASM and device changes. RESULTS: Of 196 approached participants, 146 met eligibility criteria and were included in the study. Mean (SD) participant age was 40 (12) years, and epilepsy was diagnosed at a mean (SD) age of 19.8 (13.6) years. The cohort had 84 (57.5%) female participants. A total of 35 participants had implantable devices; 1 had epilepsy surgery during the study. Of 146 participants, 128 provided sufficient seizure data for analysis, and 2 were excluded as outliers. Seizure frequency was reduced in 86 participants (68.3%) during the second half of study participation compared to the first half. In the overall cohort, mean modeled monthly seizure frequency percentage reduction was 68.73% (95% CI, 52.92%-84.54%). From 0 to 12 months (cohort 1), mean modeled percentage reduction was 67.76% (95% CI, 19.42%-116.09%); for 12 to 24 months (cohort 2), 36.00% (95% CI, 9.27%-53.46%); and for longer than 24 months (cohort 3), 66.03% (95% CI, 48.25%-83.80%) (all P < .001). An ASM was added in 69 participants (54.7%), of whom 46 (66.7%) experienced seizure frequency reduction, including seizure freedom. Seizure trajectories in participants with devices did not significantly differ from those without devices. CONCLUSIONS AND RELEVANCE: Findings from the HEP2 study imply that FTRE improves over time, ASM additions had low probability of achieving seizure freedom but contributed to seizure reduction, and device-treated participants exhibited similar seizure trajectories to those without devices. Whether improvements reflected the natural history of FTRE or active management remains unclear, but our findings suggest cautious interpretation of open-label studies positing disease-modifying effects and further research into FTRE treatment response.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Potnis O, Biondo G, Sukonik R, et al. Seizure Frequency Trends Over Time in Treatment-Resistant Focal Epilepsy. JAMA Neurol. 2025. PMID: 41114972. doi:10.1001/jamaneurol.2025.4085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。